Breast Cancer Clinical Trial
— CARIATIDEOfficial title:
An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman
This observational study is restricted to postmenopausal women with hormone-sensitive early breast cancer, who have decided to take prescribed adjuvant use of AIs, anastrozole or letrozole, according to the current product SmPCs. There is no Investigational Medicinal Product (IMP) to be taken in this observational study. The adjuvant AI medication must not have exceeded thirteen weeks. In CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily practicE through Educational approach), impact of educational material on women's compliance and persistence rates will be evaluated.
Status | Completed |
Enrollment | 2600 |
Est. completion date | May 2011 |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Postmenopausal woman with hormone sensitive early breast cancer - Documented decision of treatment with upfront adjuvant AI (either anastrozole or letrozole) according to current SmPC OR current treatment with AI (either anastrozole or letrozole) according to current SmPC, that has not exceeded thirteen weeks Exclusion Criteria: - Upfront adjuvant AI medication which has exceeded thirteen weeks at randomisation - Concomitant adjuvant treatment with tamoxifen or exemestane - Previous use of adjuvant tamoxifen or exemestane exceeding thirteen weeks |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Brisbane | Queensland |
Australia | Research Site | Canberra | Australian Capital Territory |
Australia | Research Site | Coffs Harbour | New South Wales |
Australia | Research Site | Hobart | Tasmania |
Australia | Research Site | Nambour | Queensland |
Australia | Research Site | Newcastle | New South Wales |
Australia | Research Site | Port Macquarie | New South Wales |
Australia | Research Site | Toowoomba | Queensland |
Australia | Research Site | Tweed Heads | New South Wales |
Austria | Research Site | Linz | Upper Austria |
Austria | Research Site | Salzburg | |
Austria | Research Site | St. Veit | Carinthia |
Austria | Research Site | Vienna | |
Austria | Research Site | Weiz | Styria |
Austria | Research Site | Wolfsberg | Carinthia |
Belgium | Research Site | Aalst | |
Belgium | Research Site | Antwerpen | |
Belgium | Research Site | Arlon | |
Belgium | Research Site | Bonheiden | |
Belgium | Research Site | Bornem | |
Belgium | Research Site | Boussu | |
Belgium | Research Site | Brussels | |
Belgium | Research Site | Charleroi | |
Belgium | Research Site | Dendermonde | |
Belgium | Research Site | Edegem | |
Belgium | Research Site | Eupen | |
Belgium | Research Site | Geel | |
Belgium | Research Site | Gent | |
Belgium | Research Site | Geraardsbergen | |
Belgium | Research Site | Gilly | |
Belgium | Research Site | Haine St Paul | |
Belgium | Research Site | Leuven | |
Belgium | Research Site | Li?ge | |
Belgium | Research Site | Libramont | |
Belgium | Research Site | Namur | |
Belgium | Research Site | Oostende | |
Belgium | Research Site | Ottignies | |
Belgium | Research Site | Overpelt | |
Belgium | Research Site | Rocourt | |
Belgium | Research Site | Seraing | |
Belgium | Research Site | Tournai | |
Belgium | Research Site | Turnhout | |
Chile | Research Site | Santiago | Metropolitana |
Chile | Research Site | Temuco | Novena Region |
Colombia | Research Site | Barranquilla | Atlantico |
Colombia | Research Site | Bogota | Cundinamarca |
Colombia | Research Site | Cali | Valle |
Colombia | Research Site | Medellin | Antioquia |
Colombia | Research Site | Neiva | Huila |
Colombia | Research Site | Pasto | Nari?o |
Croatia | Research Site | Osijek | |
Croatia | Research Site | Rijeka | |
Croatia | Research Site | Zagreb | |
Czech Republic | Research Site | Hradec Kralove | |
Czech Republic | Research Site | Opava | |
Czech Republic | Research Site | Ostrava | |
Czech Republic | Research Site | Praha | |
Finland | Research Site | Helsinki | |
Finland | Research Site | Tampere | |
France | Research Site | Aix En Provence | |
France | Research Site | Ales | |
France | Research Site | Annecy | |
France | Research Site | Arpajon | |
France | Research Site | Avignon | |
France | Research Site | Beauvais | |
France | Research Site | Bordeaux | |
France | Research Site | Brest | |
France | Research Site | Brive La Gaillarde | |
France | Research Site | Colmar | |
France | Research Site | Creteil | |
France | Research Site | Cucq | |
France | Research Site | Dechy | |
France | Research Site | Evreux | |
France | Research Site | GAP | |
France | Research Site | Grenoble | |
France | Research Site | Hyeres | |
France | Research Site | La Seyne Sur Mer | |
France | Research Site | Limoges | |
France | Research Site | Lyon | |
France | Research Site | Mareuil Les Meaux | |
France | Research Site | Marseille | |
France | Research Site | Mont de Marsan | |
France | Research Site | Mougins | |
France | Research Site | Nancy | |
France | Research Site | Nantes | |
France | Research Site | Narbonne | |
France | Research Site | Nice | |
France | Research Site | Nimes | |
France | Research Site | Perigueux | |
France | Research Site | Perpignan | |
France | Research Site | Quimper | |
France | Research Site | Reims | |
France | Research Site | Rennes | |
France | Research Site | Rouen | |
France | Research Site | Saint Brieux | |
France | Research Site | Saint Cyr Sur Loire | |
France | Research Site | Saint Gregoire | |
France | Research Site | Saint Jean | |
France | Research Site | Saint Mande | |
France | Research Site | Saint Nazaire | |
France | Research Site | Strasbourg | |
France | Research Site | Thonon Les Bains | |
France | Research Site | Toulon | |
France | Research Site | Toulouse | |
France | Research Site | Valence | |
France | Research Site | Vannes | |
France | Research Site | Villeneuve Sur Lot | |
Greece | Research Site | Athens | |
Greece | Research Site | Patras | Achaia |
Greece | Research Site | Piraeous | |
Greece | Research Site | Thessaloniki | |
Greece | Research Site | Trikala | |
Italy | Research Site | Bologna | |
Italy | Research Site | Cosenza | |
Italy | Research Site | Lido di Camaiore | Lucca |
Italy | Research Site | Pavia | |
Italy | Research Site | Roma | |
Italy | Research Site | Treviso | |
Peru | Research Site | Lima | |
Peru | Research Site | Piura | |
Romania | Research Site | Alba-Iulia | |
Romania | Research Site | Baia Mare | |
Romania | Research Site | Bucuresti | |
Romania | Research Site | Cluj-Napoca | |
Romania | Research Site | Oradea | |
Romania | Research Site | Suceava | |
Sweden | Research Site | Karlskrona | |
Sweden | Research Site | Skellefte? | |
Sweden | Research Site | Stockholm | |
Switzerland | Research Site | Baden | |
Switzerland | Research Site | Bern | |
Switzerland | Research Site | Lugano | |
Switzerland | Research Site | St. Gallen | |
Switzerland | Research Site | Zurich | |
Turkey | Research Site | Ankara | |
Turkey | Research Site | Diyarbakir | |
Turkey | Research Site | Eskisehir | |
Turkey | Research Site | Gaziantep | |
Turkey | Research Site | Istanbul | |
Turkey | Research Site | Izmir | |
Turkey | Research Site | Kayseri | |
Turkey | Research Site | Konya | |
Turkey | Research Site | Malatya | |
Turkey | Research Site | Mersin | |
United Kingdom | Research Site | Brighton | |
United Kingdom | Research Site | Bristol | |
United Kingdom | Research Site | Cardiff | |
United Kingdom | Research Site | Cheltenham | |
United Kingdom | Research Site | Coventry | |
United Kingdom | Research Site | Dundee | |
United Kingdom | Research Site | Edinburgh | |
United Kingdom | Research Site | Glasgow | |
United Kingdom | Research Site | Liverpool | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Macclesfield | |
United Kingdom | Research Site | Manchester | |
United Kingdom | Research Site | Northwood | |
United Kingdom | Research Site | Nottingham | |
United Kingdom | Research Site | Scarborough | |
United Kingdom | Research Site | Shrewsbury | |
United Kingdom | Research Site | St Albans | Hertfordshire |
United Kingdom | Research Site | York | |
Venezuela | Research Site | Caracas | Distrito Capital |
Venezuela | Research Site | Valencia | Estado Carabobo |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Australia, Austria, Belgium, Chile, Colombia, Croatia, Czech Republic, Finland, France, Greece, Italy, Peru, Romania, Sweden, Switzerland, Turkey, United Kingdom, Venezuela,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The compliance rate for the adjuvant AI medication will be analysed at one year based on the subject's assessment. | once after one year | No | |
Secondary | Persistence rate will be evaluated for the first time after one year and a second time after two years. The Investigator will ask the subject about her persistence as follows: | After one and two years. | No | |
Secondary | Time to treatment discontinuation is defined as number of days between the date of first and last intake of AI medication. Dates for AI treatment start and discontinuation will be documented in the CRF. | After one and two years | No | |
Secondary | Reasons for discontinuation of AI: recurrence, death, physician's recommendation, interactions with other medication, side effects, treatment with other hormone medication than anastrozole or letrozole, unfilled AI prescription, subject's wish, other. | After one and two years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |